A short treatment study of aripiprazole in pediatric patients with schizophrenia

A multicenter, double-blind, randomized, dose-comparison study of three different doses of aripiprazole orally administered over 6 weeks in pediatric patients with schizophrenia

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221112

Enrollment

Registered

2010-05-27

Start date

2010-05-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

investigational material(s) Generic name etc : aripiprazole INN of investigational material : Therapeutic category code : 117 Psychotropic agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with a diagnosis of schizophrenia according to DSM-IV-TR 2) Male and female patients aged 13-17 years 3) Inpatient or outpatient status

Exclusion criteria

Exclusion criteria: 1) Patients who have a diagnosis of any other disease except schizophrenia according to DSM-IV-TR 2) Patients who fall under a contraindication listed in the ABILIFY package insert

Design outcomes

Primary

Measure	Time frame
PANSS total sore change from baseline in final judgement	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026